VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025

VYNE Therapeutics Inc.

2024-Q2 EPS reported -$0.37 revenue$296,000

Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.
Cash, cash equivalents, restricted cash and marketable securities of $78.1M as of June 30, 2024.
Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo; top-line results expected mid-2025.
Phase 1a SAD/MAD trial of VYN202 ongoing; SAD data in Q3 2024, MAD data in Q4 2024.
Appointed Dr. Subhashis Banerjee as SVP of Clinical Development; previously at Bristol Myers Squibb.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.